A Randomized, Blinded, Placebo-controlled, Cross-over Study of the Safety and Immunogenicity of Trivalent, Inactivated Influenza Vaccine for 2010-2011.
Phase of Trial: Phase II
Latest Information Update: 23 Apr 2015
At a glance
- Drugs GSK 1536489A (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics
- 29 Oct 2010 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
- 29 Oct 2010 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 16 Jun 2010 New trial record